science
Elicio Shares Fall After Pancreatic Cancer Vaccine Misses Mid-Stage Primary Endpoint
Elicio shares declined after its pancreatic cancer vaccine failed to meet primary and key efficacy endpoints in a mid-stage clinical trial, according to @Reuters reported.
The GuardianAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Elicio shares declined following the release of mid-stage study results for its pancreatic cancer vaccine. The vaccine did not meet the primary endpoint or key efficacy thresholds in the mid-stage study. The study was a mid-stage (Phase 2-equivalent) clinical trial evaluating the pancreatic cancer vaccine.
@Reuters reported the share decline occurred after the company disclosed the trial outcomes.
Transparency
1 source · single source
CorroborationModerate · 1 source
